Navigation Links
IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
Date:4/27/2012

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).

Glaucoma is the leading cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million people worldwide are afflicted with the disease today.

MLT was first introduced by IRIDEX in its infrared laser platforms, but recent technology advancements have now made it available with the IRIDEX green laser system (IQ 532), our most versatile and highest selling laser used by the broadest group of ophthalmologists. The unique ability of the IQ 532 to offer tissue-sparing repeatable therapies for both glaucoma and retinal diseases represents a market breakthrough as well as providing ophthalmologists a very high return on their capital investment, said Dr. Dominik Beck, IRIDEX President and CEO.

David Gossage, M.D., medical director of the Gossage Eye Institute, noted that the addition of the MicroPulse module to the IQ 532 system makes it a valid option for a much broader patient population than has historically been the case.

"Compared to other lasers used for the treatment of glaucoma, the IQ 532 with the MicroPulse module offers greater versatility because it can also be used for a range of other conditions including diabetic macular edema, proliferative diabetic retinopathy, and retinal tears," Dr. Gossage said.  "I'm comfortable offering MLT to glaucoma patients as a first-line option because of its potential to reduce intraocular pressure without causing tissue damage."

MLT produces laser pulses at very short durations to create a therapeutic response of lowering the intra-ocular pressure of a glaucoma patient without thermal damage. 

About MicroPulse Technology

MicroPulse is a tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

 About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the our growth strategy, the addressable market of our products and MicroPulse laser therapy.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX to Present at Upcoming Investment Conferences
2. IRIDEX Reports 2011 Fourth Quarter and Year-End Results
3. IRIDEX Announces Fourth Quarter and Full Year 2011 Conference Call and Release Date
4. IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC)
5. IRIDEX to Present at the Sidoti & Company New York Micro Cap Conference
6. Cutera and IRIDEX Announce Acquisition of IRIDEX Aesthetic Business Unit
7. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
8. IRIDEX Signs License and Distribution Agreement with Leader in Eye Care
9. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
10. IRIDEX Announces Third Quarter 2011 Conference Call and Release Date
11. IRIDEX Launches New MicroPulse™ Module Targeting the Broad Ophthalmology Laser Photocoagulation Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... endovascular medical technology, today announced Food and Drug ... cardiac resynchronization defibrillator that provides heart failure patients ... scans. Iperia devices also have remote monitoring with ... that adapts the heart rate in response to ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... of extending care beyond the implant at the Heart ... 4-7 in San Francisco . ... delivering the highest quality of patient care and satisfaction ... cared for each and every tomorrow," said Marlou ...
(Date:5/3/2016)... 2016 Pharmaceutical giant Johnson & ... a woman who says its talc-based powder products caused ... Ristesund $5 million in compensatory damages and $50 ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This is the ... In February, the same court awarded $72 million to ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... 2016, a powerful cellular therapy software application that helps blood and marrow transplant ... , Since Transtem’s initial launch, Mediware has continued to enhance core application features. ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on Obesity and ... 2016 at Las Vegas. It aims to bring together academicians, scientists, dietitians, surgeons, ... organizations across the globe; making the conference a perfect platform to share experience ...
(Date:5/3/2016)... ... May 04, 2016 , ... The National Association of Professional Women (NAPW) ... of the Year Circle. She is recognized with this prestigious distinction for leadership in ... than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome ...
(Date:5/3/2016)... ... , ... Sue Desmond-Hellmann, chief executive officer of the Bill & Melinda Gates ... possibility in her keynote address at Georgia State University’s spring commencement on ... rich experience as a scientist, physician and executive, Desmond-Hellmann leads the Gates Foundation’s efforts ...
(Date:5/3/2016)... Baltimore, Md. (PRWEB) , ... May 03, 2016 , ... ... devastating consequences of inappropriate or excessive levels of alcohol use. Alcohol and its ... fetal alcohol spectrum disorders to the susceptibility to strokes in those 65 years and ...
Breaking Medicine News(10 mins):